值得注意的是，启明医疗此前宣布，集团于近日已就Cardiovalve经导管三尖瓣置换系统正式向欧洲公告 机构递交CE MDR认证的全部申请资料，标志着该产品在欧洲市场的准入进程迈出关键一步，也意味着 启明医疗在已成熟的主瓣、肺瓣产品线基础上，进一步完善了三尖瓣治疗矩阵。 智通财经APP获悉，启明医疗-B(02500)尾盘涨超10%，截至发稿，涨9.8%，报3.36港元，成交额1376.76 万港元。 消息面上，堃博医疗拟以总代价1500万美元，向启明医疗收购德晋医疗1.05%股权。启明医疗表示，作 为被投资公司的少数财务投资者，出售事项为本集团变现其投资的适当机会：透过剥离非核心业务投 资，本集团将能够加强其现金流，改善其营运资金状况，提升整体财务灵活性，并促进资源重新分配至 其核心业务。 ...

Core Viewpoint - The stock of Qiming Medical-B (02500) rose over 10% in late trading, currently up 9.8% at HKD 3.36, with a trading volume of HKD 13.76 million [1] Group 1: Investment Activity - Kunbo Medical plans to acquire a 1.05% stake in Qiming Medical for a total consideration of USD 15 million [1] - Qiming Medical stated that the sale represents an appropriate opportunity to monetize its investment as a minority financial investor [1] Group 2: Financial Strategy - By divesting non-core business investments, Qiming Medical aims to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Product Development - Qiming Medical has submitted all application materials for CE MDR certification of the Cardiovalve transcatheter tricuspid valve replacement system to the European notification agency, marking a significant step in the product's market entry process in Europe [1] - This development further enhances Qiming Medical's treatment matrix for tricuspid valves, building on its established mitral and pulmonary valve product lines [1]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The treatment equipment industry in China has experienced significant growth, with the market size increasing from 375.23 billion RMB in 2019 to 621.39 billion RMB in 2023, reflecting a compound annual growth rate (CAGR) of 13.44% [9] - The market is expected to continue growing, with projections indicating an increase to 872.09 billion RMB by 2028, at a CAGR of 6.12% [10] - The integration of AI and advanced technologies is driving innovation and efficiency in treatment devices, enhancing diagnostic accuracy and treatment precision [31] Market Background - The medical device sector includes instruments and software for diagnosis, monitoring, and treatment, with a notable increase in clinical trial institutions from 1,176 in 2022 to 1,340 in 2023, a growth of 13.8% [5] - The treatment equipment category encompasses surgical instruments and rehabilitation devices, which are crucial for patient recovery [6][7] Market Status - The treatment equipment market is expanding due to improved regulatory frameworks and increased domestic innovation, with a total of 13,260 medical device registrations in 2023, a 25.4% increase from 2022 [9] - The demand for treatment devices is rising, driven by an aging population and increased surgical procedures, with PCI surgeries growing from 915,000 in 2018 to 1,636,000 in 2023, a 26.4% year-on-year increase [13] Market Competition - The competitive landscape features a tiered structure, with leading companies like Mindray Medical and MicroPort in the first tier, and others like Qizhi Laser and Yuyue Medical in subsequent tiers [17][18] - The total R&D investment among the top 20 listed medical device companies reached 11.18 billion RMB in 2023, up 14.9% from 2022, indicating a strong focus on innovation [18] Recommended Brands - Mindray Medical is recognized for its leadership in ultrasound imaging and life information support, with a significant market share in high-end ultrasound products [19] - MicroPort specializes in minimally invasive intervention technologies, particularly in cardiovascular and neurological fields [20] - Yuyue Medical leads in home medical devices, with a dominant market position in respiratory therapy and blood glucose monitoring [22] Development Trends - The industry is undergoing a technological revolution with AI, 5G, and IoT integration, enhancing diagnostic and treatment capabilities [31] - The shift towards tiered medical services is optimizing the structure of healthcare consumption, with increased procurement of high-end devices by tertiary hospitals [32] - National policies are fostering domestic innovation and internationalization in the medical device sector, with a focus on streamlining approval processes for innovative products [33]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州啓明醫療器械股份有限公司 (「本公司」) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02500 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 2. 股份分類 | 普通股 | 股份類 ...

格隆汇12月29日丨启明医疗-B(02500.HK)公告，于2025年12月29日，卖方啓明医疗(香港)有限公司(为公 司的全资附属公司)与买方Broncus China Holding Corporation订立股份转让协议，据此，卖方同意出售而 买方同意购买销售股份(Valgen的157,800股B轮优先股)，代价为1500万美元，占被投资公司Valgen Holding Corporation于本公告日期已发行股份总数(按全面摊薄及已转换基准)约1.05%。 ...

Core Viewpoint - The company, Qiming Medical, is divesting a minority stake in Valgen Holding Corporation to focus on its core business and improve financial flexibility through the sale of non-core investments [1] Group 1: Transaction Details - Qiming Medical (Hong Kong) Limited has entered into a share transfer agreement with Broncus China Holding Corporation to sell shares for a total consideration of $15 million, representing approximately 1.05% of the total issued shares of Valgen Holding Corporation as of the announcement date [1] - Valgen Holding Corporation is a Cayman Islands registered company primarily engaged in providing systemic solutions for mitral and tricuspid regurgitation [1] Group 2: Strategic Rationale - The company aims to reallocate resources to develop its core products and support long-term business growth by streamlining its investment portfolio [1] - The board believes that prudent capital management, including this divestment, will enhance the company's sustainable development and strengthen shareholder returns [1]

Core Viewpoint - Qiming Medical-B (02500) announced a share transfer agreement where Qiming Medical (Hong Kong) Limited will sell shares to Broncus China Holding Corporation for $15 million, representing approximately 1.05% of the total issued shares of Valgen Holding Corporation as of the announcement date [1] Group 1: Investment Details - The transaction involves the sale of shares for a total consideration of $15 million [1] - The investment company Valgen Holding Corporation is registered and incorporated under Cayman Islands law and primarily provides systemic solutions for mitral and tricuspid regurgitation [1] Group 2: Strategic Focus - The company aims to reallocate resources to develop its core products and support long-term business growth by streamlining its investment portfolio [1] - As a minority financial investor in Valgen, the sale represents an appropriate opportunity for the group to monetize its investment [1] - By divesting non-core business investments, the group expects to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Capital Management - The board believes that prudent capital management, including this sale, is beneficial for ensuring the sustainable development of the group and enhancing shareholder returns [1]

格隆汇12月29日丨启明医疗-B(02500.HK)公告，于2025年12月29日，卖方啓明医疗(香港)有限公司(为公 司的全资附属公司)与买方Broncus China Holding Corporation订立股份转让协议，据此，卖方同意出售而 买方同意购买销售股份(Valgen的157,800股B轮优先股)，代价为1500万美元，占被投资公司Valgen Holding Corporation于本公告日期已发行股份总数(按全面摊薄及已转换基准)约1.05%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 有關出售被投資公司股份之 須予披露交易 出售事項 於 二 零 二 五 年 十 二 月 二 十 九 日（交 易 時 段 後），賣 方 與 買 方 訂 立 股 份 轉 讓 協 議，據 此，賣方同意出售而買方同意購買銷售股份，代價為15,000,000美元，佔被投資公 司 於 本 公 告 日 期 已 發 行 股 份 總 數（按 全 面 攤 薄 及 已 轉 換 基 準）約1.05%。 上市規則的涵義 由 於 出 售 事 項 的 最 高 適 用 百 分 比 率（根 據 上 市 規 則 第14.07條 計 算）超 過5%但低於 25%，故訂立股份轉讓協議及其項下擬進行的出售事項構成本公司的須予披露 交 ...

（文章来源：每日经济新闻） 每经AI快讯，启明医疗-B(02500.HK)盘中涨超7%，截至发稿涨4.05%，报2.57港元，成交额489.42万港 元。 ...